Press Release

Global Good Fund, the Feinstein Institute and Sanguistat Announce New Bioelectronic Treatment Initia

November 22, 2016 Bellevue, WA

The Global Good Fund, The Feinstein Institute for Medical Research at Northwell Health and Sanguistat, Inc, are partnering on clinical trials of the Neural Tourniquet to evaluate the efficacy of bioelectronic medicine in treating blood loss associated with postpartum hemorrhage.

The Global Good Fund, The Feinstein Institute for Medical Research at Northwell Health and Sanguistat, Inc, are partnering on clinical trials of the Neural Tourniquet to evaluate the efficacy of bioelectronic medicine in treating blood loss associated with postpartum hemorrhage.

“Postpartum hemorrhage is the leading cause of maternal deaths worldwide. It kills close to 80,000 women in Africa and Asia, and around 6,000 in the U.S. each year,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institute. “Lab tests show that vagus nerve stimulation in mothers suffering from postpartum hemorrhage may reduce life-threatening bleeding.”

The Neural Tourniquet is a medical device that uses electronic nerve stimulation to reduce blood loss. Similar applications of bioelectronic medicine are already being used to treat epilepsy, depression, and cluster and migraine headache, and hold promise for treating rheumatoid arthritis and other diseases where inflammation plays a critical role. The ‘Tourniquet’ was licensed to Sanguistat, Inc, for development from the Feinstein Institute, where the initial research was conducted and where clinical trials are underway. Global Good will advise on the clinical trial and product’s potential introduction into developing regions.

Sanguistat President and CEO Ronald M. Burch, PhD, said, “The Neural Tourniquet could represent a major breakthrough in treating bleeding. If successful, it would have tremendously positive implications, not only for women giving birth, but also for soldiers wounded in battle, for patients in emergency rooms, and for patients with chronic bleeding diseases such as hemophilia. We are delighted to partner with Global Good and the Feinstein Institute to make this much-needed therapy available for developing regions.”

“All postpartum hemorrhage deaths are tragic, but they are all too common in low-income countries, where many women suffer from anemia and lack access to the necessary obstetric care. When these mothers die, the tragedy also impacts their children’s health and education, and perpetuates the cycle of poverty,” said David Bell, director of Global Health Technologies at Global Good. “If this technology proves successful, the partnership with the Feinstein Institute and Sanguistat could mean the difference between life and death for mothers around the world who suffer from postpartum hemorrhage.”

More Buzz From IV

Top Nine Invention Stories from March

March marks Women’s History Month and International Women’s Day celebrations around the world. At Intellectual Ventures, we commend the contributions of women to the field of invention, and work to support more women and girls to pursue careers in STEM.

Read More
Inventor Superhero: Dr. Forrest Bird

We’re featuring one of our favorite posts highlighting Dr. Forrest Bird. Bird invented breathing devices that have saved countless people facing medical issues affecting their hearts and lungs.

Read More
Cuba, Metamaterials, Silkworms and More: Twelve Must-Read Stories From October

CEO and founder Nathan Myhrvold said, “Every great idea starts off as a spark. We live in a society that has been completely technologically transformed by ideas that worked out.” Our favorite links this month tell stories of inventors and inventions that embody that kind of transformation.

Read More